← All trials
NCT06188715
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 14, 2024
- Primary completion
- Aug 5, 2024
- Completion date
- Aug 5, 2024
- First posted
- Jan 3, 2024
- Last posted
- Aug 13, 2024
- Enrollment
- 224
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of BaselLead sponsor
- University of BaselSponsor investigator
- University of BaselCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.